about
MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity.microRNA expression in the aging mouse lung.Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids.Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma.Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate modelDeep Sequencing Insights in Therapeutic shRNA Processing and siRNA Target Cleavage Precision.Maternally imprinted microRNAs are differentially expressed during mouse and human lung developmentRapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells.Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity.Targeting the lung using siRNA and antisense based oligonucleotides.Genomic biomarkers for patient selection and stratification: the cancer paradigm.Clinical potential of oligonucleotide-based therapeutics in the respiratory system.Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense.Genomic and molecular characterization of a novel quorum sensing molecule in Bacillus licheniformis.The 3 prime paradigm of the miR-200 family and other microRNAs.Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation.Introducing EbolaCheck: potential for point-of-need infectious disease diagnosis.Field-deployable, quantitative, rapid identification of active Ebola virus infection in unprocessed blood.Profiling the Mismatch Tolerance of Argonaute 2 through Deep Sequencing of Sliced Polymorphic Viral RNAs.Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A.Oligonucleotide Therapies for the Lung: Ready to Return to the Clinic?Adjuvant synergy: the effects of nasal coadministration of adjuvants.A novel antifungal property for the Bacillus licheniformis ComX pheromone and its possible role in inter-kingdom cross-talk.Relevance of systems pharmacology in drug discoveryPredicting oligonucleotide therapeutic efficacy at the population levelMeasuring the Action of Oligonucleotide Therapeutics in the Lung at the Cell Type-Specific Level by Tissue Disruption and Cell Sorting (TDCS)
P50
Q33268852-EB92DA30-02C9-4797-84F7-5E4C29AF0058Q33287967-0A7D44A6-2349-4D51-836C-CB4EF3856C9AQ33291235-9AD5059C-31A6-43D2-BC48-58723B8B8688Q34216291-ED745D32-FDE6-4B3E-9316-C16DBEFA85DFQ34284247-59CB7330-2A28-4464-BDD4-6E56E9BDB7C3Q34402283-1D106B78-954F-40C9-B2A5-F44C7C067265Q34595147-59E7FC89-1D7E-4CD5-AAC2-97E00472EFEAQ34768042-22E8CC02-0E66-4049-8725-EA30A2B0B302Q37052581-99717DE3-A357-4BBC-B203-462293E85CF1Q37347445-948FDACF-BF0C-4FA1-BEE2-43A40433B752Q38060203-DCACA131-5B7E-4871-A167-72787A8AC44FQ38290542-226552F8-4203-46EA-967D-12E0BA79B33BQ39913361-3DD6BA16-674F-458C-9F4B-0D4AE5F3A590Q42292484-11F3CB75-95EE-4A69-B80B-F24150EA8D7EQ42732072-C95FD39C-6D1F-425B-901B-64E9D8DA1934Q43769664-1AC9F056-C078-4953-B8E3-D4BA4E08A381Q44100083-B0E18641-9AC5-4A6D-9989-72422A113C28Q44106386-A9A55E4A-BDDC-48E3-BCF3-6B76327190A7Q46238743-C4A22F64-A6C9-48D1-B1EE-886DE5602111Q46747716-D45F38BD-D7EB-409F-B22E-A121D8CFC337Q49643055-419B028B-6A17-452C-AF18-2AF568E9E90CQ51996299-53721E8A-84BB-4AD6-8B03-2EBB3A4C7D8CQ52311576-00804A94-32A4-4BD5-85C6-FCD7B01C3C32Q83617314-0D1E51EB-6673-481F-800F-F3CF29AC9B4AQ91698622-6B9677B4-B09D-4F28-A574-177EAFEA561CQ92608622-8F294656-49EA-4205-8E0C-191778F7560A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sterghios A. Moschos
@ast
Sterghios A. Moschos
@en
Sterghios A. Moschos
@es
Sterghios A. Moschos
@nl
Sterghios A. Moschos
@sl
type
label
Sterghios A. Moschos
@ast
Sterghios A. Moschos
@en
Sterghios A. Moschos
@es
Sterghios A. Moschos
@nl
Sterghios A. Moschos
@sl
altLabel
Sterghios A. Moschos
@en
Sterghios Moschos
@en
prefLabel
Sterghios A. Moschos
@ast
Sterghios A. Moschos
@en
Sterghios A. Moschos
@es
Sterghios A. Moschos
@nl
Sterghios A. Moschos
@sl
P106
P1153
15521083600
P21
P31
P496
0000-0001-6038-3785